BioSpace News Archive

Sanofi announced the completion of its acquisition of Provention Bio, Inc. The acquisition adds TZIELD, an innovative, fully owned, first-in-class therapy in type 1 diabetes to Sanofi’s core asset portfolio in General Medicines and further drives its strategic shift toward products with a differentiated profile.

CNS Pharmaceuticals, Inc. today announced that it will present at the Virtual Investor Spotlight Event - Rapidly Advancing GBM Pivotal Study on Wednesday, May 3, 2023 at 12:00 PM ET.

GRI Bio, Inc. announced that it will present at the Virtual Investor New to the Street Event on Wednesday, May 3, 2023 at 2:00 PM ET.

Lumos Pharma, Inc. (NASDAQ:LUMO), a biopharmaceutical company advancing an oral therapeutic candidate for idiopathic Pediatric Growth Hormone Deficiency (iPGHD) through Phase 2 clinical trials, announced today that interim data from its OraGrowtH210 Trial will be reviewed in an oral presentation at the 2023 Annual Meeting of the Pediatric Endocrine Society (PES), held in San Diego, California, May 5-8, 2023.

Lisata Therapeutics, Inc., a clinical-stage pharmaceutical company developing innovative therapies for the treatment of advanced solid tumors and other serious diseases, announced that David J. Mazzo, PhD, Chief Executive Officer of Lisata, will present at three upcoming conferences.

Foresight Diagnostics, Inc, a leading developer of ultrasensitive cancer detection tests, announced that it has closed an oversubscribed Series B financing round of $58.75 million.

ChromaCode, Inc., a genomics multiplexing platform company developing accessible and affordable solutions for laboratories, patients and physicians, announced today a partnership with MedGenome, to bring its innovative High Definition PCR (HDPCR™) multiplexing technology to India and the Middle East.

Building on its focus to spark curiosity in the next generation of scientists and accelerate global access to science, MilliporeSigma, the U.S. and Canada Life Science business of Merck KGaA, Darmstadt, Germany, announces eight new and expanded Signature Partnerships for 2023-2025.

Nonagen Bioscience, a cancer diagnostics company, announced that Timothy “TJ” Johnson has been named Executive Chair of the Nonagen Bioscience Corporation.

Skye Bioscience, Inc. (OTCQB: SKYE) (“Skye” or the “Company”), a pharmaceutical company developing a proprietary, synthetic cannabinoid derivative to treat glaucoma and ocular hypertension, has started dosing of the first cohort of its multiple ascending dose (“MAD”)